Want to see ZNTL full AI Analyst Report?
Top Page
Zentalis Pharmaceuticals
(NASDAQ:ZNTL)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.50
▲(148.23% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (ongoing losses and rising TTM cash burn) and a bearish technical trend (below key moving averages with negative MACD). Valuation provides limited support because losses make P/E uninformative and there is no dividend yield.
Positive Factors
Clinical pipeline progress
Enrollment completion and initiation of a confirmatory Phase 3 study advance azenosertib toward pivotal evidence and potential approval, creating identifiable development milestones and a clearer path to future commercialization.
Negative Factors
Persistent unprofitability
The company has not established recurring commercial revenue, while its cost base remains well ahead of commercialization. Renewed widening of TTM losses indicates profitability is still dependent on successful clinical development and eventual product approval.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline progress
Enrollment completion and initiation of a confirmatory Phase 3 study advance azenosertib toward pivotal evidence and potential approval, creating identifiable development milestones and a clearer path to future commercialization.
Read all positive factors
Zentalis Pharmaceuticals (ZNTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$275.22M
Dividend YieldN/A
Average Volume (3M)716.92K
Price to Earnings (P/E)―
Beta (1Y)3.35
Revenue Growth-100.00%
EPS Growth14.08%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.46
Shares Outstanding71,671,910
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.83Price Target Upside526.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.14
Revenue Forecast (FY)N/A
Zentalis Pharmaceuticals Business Overview & Revenue Model
Company Description
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops...
How the Company Makes Money
null...
Zentalis Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 67.42M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -151.00K | 0.00 | 67.42M | 0.00 | 0.00 | 0.00 |
| EBITDA | -173.46M | -144.27M | -186.17M | -247.60M | -233.58M | -207.20M |
| Net Income | -174.90M | -137.06M | -165.84M | -292.19M | -236.81M | -158.72M |
Balance Sheet | ||||||
| Total Assets | 215.33M | 288.97M | 430.34M | 562.03M | 553.46M | 472.02M |
| Cash, Cash Equivalents and Short-Term Investments | 174.61M | 245.89M | 371.08M | 482.92M | 437.37M | 340.13M |
| Total Debt | 37.69M | 39.58M | 42.65M | 45.77M | 47.33M | 45.91M |
| Total Liabilities | 71.68M | 72.76M | 93.15M | 124.64M | 119.43M | 107.54M |
| Stockholders Equity | 143.65M | 216.20M | 337.19M | 437.28M | 433.80M | 363.95M |
Cash Flow | ||||||
| Free Cash Flow | -161.12M | -125.25M | -171.08M | -208.41M | -166.30M | -160.20M |
| Operating Cash Flow | -161.05M | -125.25M | -170.86M | -207.82M | -163.75M | -154.09M |
| Investing Cash Flow | 150.82M | 131.62M | 176.56M | -44.46M | -114.18M | -18.11M |
| Financing Cash Flow | -6.65M | -4.28M | 108.00K | 237.30M | 261.04M | 178.52M |
Zentalis Pharmaceuticals Technical Analysis
Negative
1.41
Price Trends
4.33
Negative
4.16
Negative
3.13
Positive
Market Momentum
-0.21
Positive
40.47
Neutral
32.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZNTL, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 4.31, below the 50-day MA of 4.33, and below the 200-day MA of 3.13, indicating a neutral trend. The MACD of -0.21 indicates Positive momentum. The RSI at 40.47 is Neutral, neither overbought nor oversold. The STOCH value of 32.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZNTL.
Zentalis Pharmaceuticals Risk Analysis
Zentalis Pharmaceuticals disclosed 81 risk factors in its most recent earnings report. Zentalis Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zentalis Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $70.46M | 8.71 | 16.17% | ― | 26.04% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $122.14M | -12.44 | -65.73% | ― | ― | 19.64% | |
47 Neutral | $259.26M | -18.64 | -31.27% | ― | 1.32% | 59.94% | |
45 Neutral | $275.22M | -1.55 | -87.95% | ― | -100.00% | 14.08% | |
44 Neutral | $10.70M | -0.14 | -133.02% | ― | ― | ― | |
42 Neutral | $276.21M | -0.58 | 187.62% | ― | -8.79% | -195.46% |
* Healthcare Sector Average
ZNTL
Zentalis Pharmaceuticals
3.83
2.01
110.16%
MGNX
MacroGenics
4.10
2.46
150.00%
VTGN
VistaGen Therapeutics
0.24
-2.79
-91.95%
ANIX
Anixa Biosciences
3.71
0.71
23.67%
SPRO
Spero Therapeutics
1.22
-0.63
-34.05%
SRZN
Surrozen
23.99
12.49
108.61%
Zentalis Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Zentalis Pharmaceuticals Announces Major Common Stock Offering
Positive
Aug 14, 2026
On August 13, 2026, Zentalis Pharmaceuticals entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer Co. Inc. for a public offering of 23,000,000 shares of common stock at $3.50 per share, w...
Business Operations and StrategyFinancial Disclosures
Zentalis Highlights Q2 Results and Azenosertib Progress
Positive
Aug 6, 2026
On August 6, 2026, Zentalis Pharmaceuticals reported its second-quarter 2026 results and detailed progress in late-stage development of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. As of June 30, 2026, the company held $17...
Executive/Board ChangesShareholder Meetings
Zentalis Shareholders Back Directors, Auditors and Executive Pay
Positive
Jun 18, 2026
On June 16, 2026, Zentalis Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, with 49,453,766 shares represented, or about 69.47% of outstanding common stock as of the April 20, 2026 record date, ensuring a quorum for corporate go...
Executive/Board Changes
Zentalis Pharmaceuticals Expands Board, Appoints New Director
Neutral
May 27, 2026
Effective May 22, 2026, Zentalis Pharmaceuticals expanded its board of directors from six to seven members and appointed Shannon Campbell as a Class I director, with her initial term running until the 2027 annual shareholders’ meeting. She w...
Business Operations and Strategy
Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer
Positive
May 21, 2026
On May 21, 2026, Zentalis Pharmaceuticals reported Phase 1b MUIR trial data showing that adding its WEE1 inhibitor azenosertib to paclitaxel produced encouraging efficacy in heavily pre-treated, platinum-resistant ovarian cancer patients, based on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.